# Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

> **NCT02926690** · PHASE1 · RECRUITING · sponsor: **OncoTherapy Science, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

## Interventions

- **DRUG:** OTS167PO

## Key facts

- **NCT ID:** NCT02926690
- **Lead sponsor:** OncoTherapy Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-05-29
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926690, "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02926690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*